Short Interest in Genprex (NASDAQ:GNPX) Expands By 69.7%

Genprex (NASDAQ:GNPX) was the recipient of a significant increase in short interest during the month of August. As of August 14th, there was short interest totaling 62,590 shares, an increase of 69.7% from the July 30th total of 36,884 shares. Based on an average trading volume of 391,029 shares, the days-to-cover ratio is currently 0.2 days. Currently, 7.7% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Susquehanna International Group LLP raised its position in Genprex by 11.7% during the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after purchasing an additional 35,661 shares during the period. Mayflower Financial Advisors LLC bought a new position in shares of Genprex during the 1st quarter valued at approximately $36,000. Finally, Manchester Financial Inc. bought a new position in shares of Genprex during the 1st quarter valued at approximately $36,000. Institutional investors own 14.05% of the company’s stock.

Analyst Upgrades and Downgrades

GNPX has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a report on Friday, July 17th. Wall Street Zen upgraded Genprex from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Genprex presently has an average rating of “Sell”.

Genprex Price Performance

Shares of NASDAQ GNPX traded up $0.04 during midday trading on Monday, reaching $3.71. 40,705 shares of the stock traded hands, compared to its average volume of 91,217. The company’s 50 day moving average is $7.71 and its 200 day moving average is $21.75. Genprex has a one year low of $3.57 and a one year high of $1,210.00. The stock has a market capitalization of $3.04 million, a PE ratio of -0.03 and a beta of -0.88.

Genprex (NASDAQ:GNPX) last announced its quarterly earnings results on Friday, August 14th. The company reported ($9.40) earnings per share for the quarter.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.